Potential of chromosomal and matrix-based comparative genomic hybridization for molecular diagnostics in lymphomas.
Wessendorf
S
S
Deutsches Krebsforschungszentrum Heidelberg, Abt. Organisation komplexer Genome.
Lichter
P
P
Schwänen
C
C
Fritz
B
B
Baudis
M
M
Walenta
K
K
Kloess
M
M
Döhner
H
H
Bentz
M
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D002869:Chromosome Aberrations; D002877:Chromosomes, Human / Q000235:genetics / Q000648:ultrastructure; D003520:Cyclophosphamide / Q000008:administration & dosage; D004273:DNA, Neoplasm / Q000235:genetics; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D015993:Life Tables; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D008677:Metaphase; D009693:Nucleic Acid Hybridization / Q000379:methods*; D020411:Oligonucleotide Array Sequence Analysis; D011239:Prednisolone / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D011446:Prospective Studies; D016019:Survival Analysis; D014750:Vincristine / Q000008:administration & dosage
D004273:DNA, Neoplasm; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D011241:Prednisone